Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0515

-26.1%

3:58 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NTTG who wrote (11521)	9/27/2012 9:39:09 AM
From: Cal Amari	Read Replies (1) of 13111

The examination process in most countries involves a patent examiner performing a prior art search and issuing an office action (e.g., rejecting some or all claims, and/or raising formalities objections); thereafter, the patent applicant can respond to the office action by amending the claims and/or presenting arguments supporting withdrawal of the claim rejections. This back-and-forth process with a national patent office may be performed several times until the same rejections are reiterated - at that point, a rejection is typically considered final and the applicant typically has the opportunity to appeal a final rejection within the patent office (and possibly thereafter in the judicial system). Most countries also permit a patent applicant to file one or more divisional applications to pursue different claims based on the same disclosure. Note that it is typically not permitted to amend the specification of a patent application, but the claims are frequently amended during prosecution, subject to the requirement that the claims must be supported by the disclosure.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next